Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells
© Harris et al; licensee BioMed Central Ltd. 2012
Received: 6 October 2011
Accepted: 5 March 2012
Published: 5 March 2012
Medulloblastoma is the most common malignant brain tumor in children and remains a therapeutic challenge due to its significant therapy-related morbidity. Polo-like kinase 1 (PLK1) is highly expressed in many cancers and regulates critical steps in mitotic progression. Recent studies suggest that targeting PLK1 with small molecule inhibitors is a promising approach to tumor therapy.
We examined the expression of PLK1 mRNA in medulloblastoma tumor samples using microarray analysis. The impact of PLK1 on cell proliferation was evaluated by depleting expression with RNA interference (RNAi) or by inhibiting function with the small molecule inhibitor BI 2536. Colony formation studies were performed to examine the impact of BI 2536 on medulloblastoma cell radiosensitivity. In addition, the impact of depleting PLK1 mRNA on tumor-initiating cells was evaluated using tumor sphere assays.
Analysis of gene expression in two independent cohorts revealed that PLK1 mRNA is overexpressed in some, but not all, medulloblastoma patient samples when compared to normal cerebellum. Inhibition of PLK1 by RNAi significantly decreased medulloblastoma cell proliferation and clonogenic potential and increased cell apoptosis. Similarly, a low nanomolar concentration of BI 2536, a small molecule inhibitor of PLK1, potently inhibited cell growth, strongly suppressed the colony-forming ability, and increased cellular apoptosis of medulloblastoma cells. Furthermore, BI 2536 pretreatment sensitized medulloblastoma cells to ionizing radiation. Inhibition of PLK1 impaired tumor sphere formation of medulloblastoma cells and decreased the expression of SRY (sex determining region Y)-box 2 (SOX2) mRNA in tumor spheres indicating a possible role in targeting tumor inititiating cells.
Our data suggest that targeting PLK1 with small molecule inhibitors, in combination with radiation therapy, is a novel strategy in the treatment of medulloblastoma that warrants further investigation.
Medulloblastoma is the most common malignant brain tumor in children. While therapy for standard-risk patients has resulted in improved outcomes, high-risk patients do poorly . In addition, there remains significant therapy-related morbidity, particularly in very young patients. Recent genome wide analyses have identified multiple subgroups with differing outcomes [2, 3]. These studies show the genetic heterogeneity of medulloblastoma and the need for new therapeutics based on molecular signatures of these tumors. Although a variety of signaling pathways (including Sonic Hedgehog, Wnt and Notch) are known to be associated with medulloblastoma cell biology [4–6], so far new therapeutic interventions based on this knowledge have been slow to develop. Thus, the mainstays of medulloblastoma therapy continue to be surgery, radiation and cytotoxic chemotherapy . While these approaches have improved the outcomes for low-risk patients, those with high-risk disease still have suboptimal outcomes. Furthermore, cranio-spinal radiation treatment itself results in significant long-term morbidity, especially in younger children [8, 9], and chemotherapy likewise has major side effects . Thus, there is a critical need for more effective therapies to combat this disease.
To begin to address this need, we examined protein kinase gene expression by transcriptional profiling and found altered expression of multiple protein kinases in medulloblastoma patient samples. Among these kinases is aurora kinase A (AURKA), a target we have recently shown to have therapeutic value in several brain tumors [11, 12]. Given that many protein kinases are key regulators of proliferation, invasion, angiogenesis and metastasis, they represent ideal targets for molecularly targeted cancer therapy. Analysis of our previous data suggests that polo-like kinase 1 (PLK1) is a potential therapeutic target in medulloblastoma.
PLK1 is essential for mitosis. It promotes mitotic entry by phosphorylating cyclin B1 and CDK1, and it initiates mitotic exit by activating the Anaphase Promoting Complex (APC) . Overexpression of PLK1 promotes chromosome instability and aneuploidy by overriding the G2-M DNA damage and spindle checkpoints . PLK1 is overexpressed in a wide variety of cancers, and inhibition of this kinase by shRNA or chemical inhibitors decreases tumor growth both in vitro and in vivo [13–15]. Importantly, this inhibition preferentially kills cancer cells over normal cells [16, 17]. Phase I/II studies of inhibitors of PLK1 in advanced solid tumors in adults have yielded promising results [18, 19]. The role of PLK1 in pediatric tumors is less well characterized. Recent studies indicate that it is a target in the treatment of rhabdomyosarcoma and neuroblastoma [14, 20, 21].
In this study, our goal was to evaluate PLK1 as a potential therapeutic target in medulloblastoma. We determined the expression of PLK1 mRNA in two independent cohorts of medulloblastoma patients and investigated the effect of PLK1 inhibition by RNA interference (RNAi) and by the small molecule drug BI 2536 on medulloblastoma cells in vitro.
Cell lines and primary patient samples
The Daoy and D283 medulloblastoma cell lines were purchased from American Type Cell Culture (Rockville, MD). The ONS-76 medulloblastoma cell line was kindly provided by Dr. James T. Rutka (University of Toronto, Canada). D425 and D458 cell lines were kindly provided by Dr. Darell D. Bigner (Duke University Medical Center, NC). Cell lines were cultured in DMEM (Gibco, Carlsbad, CA) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA).
Gene expression microarray analysis
Sixteen patient tumor samples comprising the first cohort were evaluated for gene expression using Affymetrix U133 Plus 2.0 GeneChip microarrays as previously described . Briefly, samples were collected at the time of surgery and snap-frozen in liquid nitrogen. Ribonucleic acid was extracted from each sample using an RNeasy kit (Qiagen, Valencia, CA) and hybridized to HG-U133 Plus 2.0 GeneChips (Affymetrix, Santa Clara, CA) according to the manufacturer's instructions. Microarray data from the samples was background-corrected and normalized using the gcRMA algorithm. One probe set per gene, based on highest overall expression level across samples, was selected for use in subsequent analyses. Differential expression of genes was determined using a Student's t-test .
All 120 tumor specimens in the second cohort were obtained in accordance with the Research Ethics Board at the Hospital for Sick Children (Toronto, Canada), as described, and the N. N. Burdenko Neurosurgical Institute (Moscow, Russia) . Gene expression array data were generated and analyzed as described .
Transfection of RNAi vectors
Three siRNAs targeting PLK1 mRNA, siPLK1-A (s448), siPLK1-B (s449) and siPLK1-C (s450), and a non-targeting siRNA were transfected into medulloblastoma cell lines using the siPORT NeoFX Transfection Agent (Ambion). A final concentration of 5 nM of siRNA was transfected into the medulloblastoma cell lines. The manufacturer's suggested protocol for a reverse transfection was used with the siRNA. Of the three siRNAs targeting PLK1, siPLK1-A was used in further experiments due to its higher efficacy in inhibiting PLK1 (Additional file 1: Figure S1 [B, C, D]).
Two shRNA vectors targeting PLK1 mRNA (1073: CCGGCGAGCTGCTTAATGACGAGTTCTCGAGAACTCGTCATTAAGCAGCTCGTTTTTG and 1325: CCGGCCCGAGGTGCTGAGCAAGAAACTCGAGTTTCTTGCTCAGCACCTCGGGTTTTTG) and a non-targeting shRNA (shNTC) were purchased from the Functional Genomics Facility at the University of Colorado, Boulder, and transfected into medulloblastoma cell lines using the Lipofectamine 2000 Transfection Reagent (Invitrogen, Carlsbad, CA). The shPLK1 1325 vector was used in further experiments due to its greater inhibition of PLK1 (Additional file 1: Figure S1 [A, D]). One microgram of shRNA for a 6-well plate was transfected into the medulloblastoma cell lines. The ratio used for the forward transfections was 1 microgram of shRNA DNA: 2 μl of Lipofectamine 2000 Transfection Reagent.
Quantitative real-time polymerase chain reaction
Ribonucleic acid was isolated 48 hours after transfection using a Qiagen RNeasy kit (Valencia, CA). TaqMan gene expression primers and probes for PLK1 (Hs00153444_m1), SOX2 (Hs01053049_s1), NES (Hs00707120_s1), Nanog (Hs002387400_g1), c-Myc (Hs01570247_m1), and GAPDH (Hs99999905_m1) were purchased from Applied Biosystems (Carlsbad, CA). Assays were performed in triplicate according to the manufacturer's recommendations. GAPDH was used as an endogenous control and the gene expression relative quantity was calculated using the ΔΔCt method. Gene expression assays were performed on an ABI StepOnePlus Real-Time PCR system.
Small molecule inhibitors of PLK1
The small molecule PLK1 inhibitors BI 2536 and BI 6727 were purchased from Axon Medchem (Groninberg, Netherlands). The drugs were reconstituted in dimethyl sulfoxide (DMSO) and aliquots were stored in a desiccator at -20°C. An equivalent amount of DMSO for the highest concentration of drug was used for each experiment as a vehicle control.
Cell proliferation and apoptosis assays
Cell proliferation was determined by MTS [3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay using CellTiter 96 AQueous One Solution (Promega, Madison, WI). Seventy-two hours after transfection with siRNA, 20 μl of MTS reagent was added to the wells already containing 100 μl of media. For drug treatment, cells were plated for 24 hours before adding BI 2536 or BI 6727. Then 72 hours after the addition of the drug, 30 μl of MTS reagent were added to the wells to make a final volume of 180 μl. Plates were read using a BioTek Synergy 2 plate reader (Winooski, VT) every hour for 4 hours after the addition of the MTS reagent. Experiments were done in triplicate and background absorbance was subtracted from all wells before analysis.
For the colony formation assay, cells were transfected with shRNA for 48 hours and then plated at 500 cells per well of a 6-well plate in triplicate. For drug treatment, 500 cells per well of a 6-well plate were plated in triplicate 24 hours before addition of BI 2536. Wells were then treated with drug for 24 hours and then allowed to grow in normal culture medium. After seven days of growth, the medium was aspirated, the wells were washed with PBS, and the colonies were stained with 0.5% crystal violet/25% methanol solution. The number of colonies per well was counted using a dissecting microscope with a threshold of 50 cells necessary to constitute a colony.
Apoptosis was assessed 72 hours after siRNA transfection or after 24 hours of BI 2536 treatment followed by 24 hours in normal culture medium. Cells were counted following staining with Guava ViaCount reagent (Millipore, Billerica, MA) and the amount of apoptosis determined using Guava Nexin reagent (Millipore). Samples were run on a Guava EasyCyte Plus flow cytometer (Millipore).
Protein lysates were obtained from samples using RIPA buffer (Thermo Scientific, Rockford, IL) with protease inhibitors added. Western blotting was performed per standard methods. Antibodies for PLK1 (#4535) and Actin (MAB1501) were purchased from Cell Signaling Technology (Danvers, MA) and Millipore, respectively. Secondary antibodies conjugated to horseradish-peroxidase were used in conjunction with a chemiluminescent reagent to visualize protein bands.
Combination of BI 2536 and ionizing radiation
Tumor sphere formation
Daoy medulloblastoma cells were either transfected with shRNA or treated with 5 nM BI 2536. Forty-eight hours after transfection or drug treatment, cells were trypsinized and counted. Ten thousand cells were seeded in a low-attachment 6-well plate in neurobasal medium (Gibco) supplemented with fibroblast growth factor, 20 ng/mL (Sigma-Aldrich, St. Louis, MO), B-27 (Gibco), epidermal growth factor, 20 ng/mL (Sigma-Aldrich), and L-glutamine (Gibco). Tumor spheres were allowed to grow for 7 days. After 7 days, pictures were taken with an inverted microscope and subsequently the tumor spheres were either processed for RNA isolation, or dissociated and passaged to form secondary tumor spheres. The primary tumor spheres were dissociated with Accutase (Millipore, Scr005) and resuspended in PBS. Ten thousand cells from the primary tumor spheres were seeded on a low attachment plate. The formation of secondary tumor spheres was seen 4 days after seeding. The diameter of the tumor spheres was measured using QCapture Pro software from saved images captured at 4× maginification.
Statistical significance was determined using a Student's t-test. Error bars represent the standard error of the mean (n ≥ 3). GraphPad Prism 5 was used to calculate IC50 values and to compute the nonlinear regression equations.
Plk1 is overexpressed in medulloblastoma
We initially hypothesized that kinases involved in cell cycle regulation would be likely candidates as novel therapeutic targets in medulloblastoma. To begin to address this question, we first examined expression of cell cycle-regulated kinases in a cohort of sixteen medulloblastoma patients we had previously studied . We found that expression of PLK1 mRNA was altered in most, but not all, of our patient samples when compared to normal cerebellum (Figure 1A). There was no clear correlation between the high PLK1-expressing samples and age, gender or outcomes. Recent genomic analysis defined four major subgroups of medulloblastoma. The 4 major subgroups are Sonic Hedgehog signaling (SHH), Wnt signaling (WNT), Group C and Group D. Group C and D tend to be more aggressive than the SHH or WNT signaling groups . To further elucidate whether there was a correlation within the subgroups of medulloblastoma, we examined expression of PLK1 mRNA in a cohort of 120 recently described medulloblastoma samples . Medulloblastoma samples expressed significantly higher PLK1 mRNA compared to adult cerebellum (p < 0.00003), but PLK1 mRNA expression was not significantly higher when compared to fetal cerebellum (Figure 1B). When examined at the genomic subgroup level, there was no difference in PLK1 mRNA expression among the four major genomic subgroups (Figure 1B). These data indicate that PLK1 may be associated with the oncogenic process in general and is not specific to a particular molecular subgroup of medulloblastoma. We next evaluated expression of PLK1 mRNA in a panel of well-characterized medulloblastoma cell lines. Consistent with our patient tissue data, all medulloblastoma cell lines tested expressed PLK1 mRNA at significantly higher levels (p < 0.01) compared to normal pediatric and adult cerebellum (Figure 1C). We next examined PLK1 protein expression in normal pediatric and adult cerebellum as well as a panel of medulloblastoma cell lines. As seen in Figure 1D, pediatric cerebellum (UPN 514 and 605) and adult cerebellum have minimal PLK1 protein expression while all the medulloblastoma cell lines have increased but varied levels of PLK1 protein.
Inhibition of PLK1 suppresses medulloblastoma cell growth and colony forming ability
PLK1 inhibition induces apoptosis in medulloblastoma cells
Small molecule inhibitor BI 2536 is a potent inhibitor of medulloblastoma cell growth by increased apoptosis
To determine whether this decreased proliferation was due to apoptosis, we evaluated Annexin V expression on the surface of BI 2536-treated medulloblastoma cells by flow cytometry. Representative plots are shown in Figure 4C for Daoy and in Additional file 2: Figure S2A for ONS-76. Annexin V positive--7-aminoactinomycin D (7-AAD) negative cells, indicative of early apoptosis, were present at low levels in DMSO control-treated cells. This population increased with escalating doses of BI 2536. In addition, the Annexin V positive--7-AAD positive population was significantly enhanced in BI 2536 cells, indicating increased late apoptosis. The total percentage of apoptosis is quantified in Figure 4D and in Additional file 2: Figure S2B for Daoy and ONS-76, respectively.
BI 2536 enhances radiation sensitivity of medulloblastoma cells
Inhibition of PLK1 mRNA decreases tumor sphere formation and decreases SOX2 mRNA expression
We then analyzed the impact of BI 2536 on tumor sphere formation in the Daoy cell line. BI 2536 decreased the size of the tumor spheres (479.2 μm for the DMSO control treated vs. 142 μm for the 5 nM BI 2536 treated) consistent with the RNAi experiments (Additional file 5: Figure S5A). Interestingly, if we dissociate these primary tumor spheres and reseed them, the diameter of the serially passaged secondary tumor spheres is also significantly impaired (396.5 μm for the DMSO control treated vs. 171.4 μm for the cells previously treated with 5 nM BI 2536; Additional file 5: Figure S5B). We conclude therefore that PLK1 plays a key role in regulating stem-like characteristics of tumor cells.
Therapy-associated side effects in medulloblastoma have led to a concentrated search for novel therapeutic targets, particularly targets for which inhibition has radiosensitizing potential and minimal toxicities. Recent genomic studies have begun to unravel the molecular mechanisms involved in medulloblastoma, but have not yet resulted in novel therapeutic agents [2, 3, 27]. Analysis of protein kinase gene expression revealed that expression of multiple protein kinases was altered in medulloblastoma, including several components of the mitotic machinery such as aurora kinase A and PLK1 . Perturbing mitosis by disrupting the proper formation of mitotic spindles required for chromosome alignment and segregation has been shown to preferentially kill cancer cells .
It is well established that PLK1 plays an important role in cell cycle regulation by functioning in centrosome maturation, spindle formation, mitotic entry and cytokinesis. Elevated PLK1 levels have been found in many adult cancers, including breast and colorectal cancer, and in pediatric cancers, including neuroblastoma and rhabdomyosarcoma [20, 21, 29]. While PLK1 mRNA expression is upregulated in medulloblastoma, the significance of PLK1 in the pathogenesis and management of this pediatric brain tumor is not well understood.
In this study we demonstrate that PLK1 mRNA is overexpressed in two independent medulloblastoma cohorts when compared to normal cerebellum. Of note, fetal tissues expressed very high levels of PLK1 mRNA compared to adult brain tissues. This may reflect the critical role PLK1 in regulating mitosis. Indeed PLK1 is essential for progression into mitosis during embryonic development. PLK1-deficient cells displayed mitotic infidelity resulting in mitotic arrest and finally death during zebrafish embryogenesis . Furthermore, PLK1 homozygous null mice were found to be embryonic lethal and the incidence of tumors in PLK1 heterozygotes was three-fold greater than that in their wild-type counterparts, again emphasizing the importance of PLK1 in normal embryogenesis and development . Interestingly, not all tumor samples overexpressed PLK1 mRNA, further emphasizing the molecular heterogeneity of this tumor.
Decreasing the expression of PLK1 mRNA by RNAi clearly resulted in growth suppression and induction of apoptosis in medulloblastoma cells. Furthermore, we show that inhibition of PLK1 by a small molecule inhibitor, BI 2536, results in a significant reduction in the proliferation of medulloblastoma cells both in short-term and long-term assays. Importantly, IC50 values were in the low nanomolar range, which is in line with achievable therapeutic plasma concentrations demonstrated in clinical phase I/II trials of BI 2536 . Treatment with 5 nM BI 2536 in Daoy and 7.5 nM in ONS-76 medulloblatoma cells induced apoptosis, which is consistent with results found in other cancer cells .
BI 2536 (Boehringer Ingelheim, Ingelheim, Germany) is a first-in-class PLK1 inhibitor. Not only is it an ATP-competitive kinase inhibitor that inhibits the enzymatic activity of PLK1, it also shows over 1,000-fold selectivity for PLK1 against a large panel of other tyrosine and serine/threonine kinases [18, 29]. In dose-escalation Phase I trials, BI 2536 was well tolerated . Several Phase II studies are underway or have recently been completed for BI 2536 . In addition to BI 2536, there are several other inhibitors of PLK1 in development and undergoing clinical testing. These include BI 6727 (Boehringer Ingelheim, Ingelheim, Germany), GSK461364 (GlaxoSmithKline, Middlesex, UK) and HMN-214 (Nippon Shinyaku Co. Ltd, Kyoto, Japan). However, there are currently no clinical studies of PLK1 inhibitors in any pediatric cancers. Our data and those of Ackermann, et al., and Hu, et al., strongly argue for development of such studies in pediatric solid tumors [20, 21]. In particular our data show that PLK1 is a target in all subgroups of medulloblastomas making it ideal for clinical trials.
Radiation is a key component of medulloblastoma therapy. Unfortunately, it results in significant morbidity, particularly in very young patients . Thus, agents that radiosensitize medulloblastoma cells would be of great utility. Here we show that low nanomolar concentrations of BI 2536 strongly decreased the surviving fraction of tumor cells in response to radiation and increased the sensitizer enhancement ratios. These results indicate that BI 2536 can effectively enhance medulloblastoma cell radiosensitivity in vitro. These data are in accordance with previous studies showing increased radiosensitivity in malignant cells depleted of PLK1 mRNA by RNAi .
It has been hypothesized that medulloblastoma tumors contain stem cell-like tumor-initiating cells that are more resistant to therapy [33, 34]. Here we found that inhibition of PLK1 expression significantly decreased the tumor sphere size and decreased the expression of the stem cell marker SOX2. Interestingly, the decrease in stem cell markers was more pronounced in tumor spheres than in monolayer cells cultured in normal adherent conditions. Thus, there is a clear role for PLK1 in tumor-initiating cells, a finding hinted at in recent data from neuroblastoma . It will be important to elucidate in detail the specific mechanisms by which PLK1 mediates tumor-initiating cell growth.
In total, our data make a strong argument for further exploring the role of PLK1 inhibition in medulloblastoma. Regarding the PLK1 inhibitors, a second PLK1 inhibitor, BI 6727, has been used in several studies . BI 6727 is similar to BI 2536 in its in vitro activity in Daoy and ONS-76 medulloblastoma cell lines (Additional file 6: Figure S6). In in vivo studies, BI 6727 shows better toxicity and pharmacokinetic profile compared to BI 2536. The next step will be to perform carefully constructed animal studies. We plan to perform orthotopic cerebellar xenograft in vivo studies with BI 6727. We will especially take in to consideration dosing schedules and pharmacodynamic marker evaluation. These data will assist in developing future clinical trials.
Our data, together with previous studies, strongly suggest that targeting PLK1 with small molecule inhibitors in combination with radiation therapy is both a novel strategy in the treatment of medulloblastoma and one that warrants further study.
This work was supported by NIH KO8NS59790-3 (RV) and The Morgan Adams Foundation (RV, NKF).
- Dhall G: Medulloblastoma. J Child Neurol. 2009, 24 (11): 1418-1430. 10.1177/0883073809341668.View ArticlePubMed
- Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, et al: Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011, 29 (11): 1408-1414. 10.1200/JCO.2009.27.4324.View ArticlePubMed
- Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L, Eberhart CG, et al: Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2010, 29 (11): 1424-1430.PubMed CentralView ArticlePubMed
- Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM, Eberhart CG: Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006, 66 (15): 7445-7452. 10.1158/0008-5472.CAN-06-0858.View ArticlePubMed
- Wolter M, Reifenberger J, Sommer C, Ruzicka T, Reifenberger G: Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 1997, 57 (13): 2581-2585.PubMed
- Wodarz A, Nusse R: Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol. 1998, 14: 59-88. 10.1146/annurev.cellbio.14.1.59.View ArticlePubMed
- Packer RJ: Progress and challenges in childhood brain tumors. J Neurooncol. 2005, 75 (3): 239-242. 10.1007/s11060-005-6745-9.View ArticlePubMed
- Ris MD, Packer R, Goldwein J, Jones-Wallace D, Boyett JM: Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. J Clin Oncol. 2001, 19 (15): 3470-3476.PubMed
- Mulhern RK, Palmer SL, Merchant TE, Wallace D, Kocak M, Brouwers P, Krull K, Chintagumpala M, Stargatt R, Ashley DM, et al: Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol. 2005, 23 (24): 5511-5519. 10.1200/JCO.2005.00.703.View ArticlePubMed
- Packer RJ, Cogen P, Vezina G, Rorke LB: Medulloblastoma: clinical and biologic aspects. Neuro Oncol. 1999, 1 (3): 232-250.PubMed CentralView ArticlePubMed
- El-Sheikh A, Fan R, Birks D, Donson A, Foreman NK, Vibhakar R: Inhibition of Aurora Kinase A enhances chemosensitivity of medulloblastoma cell lines. Pediatr Blood Cancer. 2010, 55 (1): 35-41.PubMed
- Barton VN, Foreman NK, Donson AM, Birks DK, Handler MH, Vibhakar R: Aurora kinase A as a rational target for therapy in glioblastoma. J Neurosurg Pediatr. 2010, 6 (1): 98-105. 10.3171/2010.3.PEDS10120.View ArticlePubMed
- Strebhardt K: Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov. 2010, 9 (8): 643-660. 10.1038/nrd3184.View ArticlePubMed
- Grinshtein N, Datti A, Fujitani M, Uehling D, Prakesch M, Isaac M, Irwin MS, Wrana JL, Al-Awar R, Kaplan DR: Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res. 2011, 71 (4): 1385-1395. 10.1158/0008-5472.CAN-10-2484.View ArticlePubMed
- Degenhardt Y, Lampkin T: Targeting Polo-like kinase in cancer therapy. Clin Cancer Res. 2010, 16 (2): 384-389. 10.1158/1078-0432.CCR-09-1380.View ArticlePubMed
- Liu X, Lei M, Erikson RL: Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol. 2006, 26 (6): 2093-2108. 10.1128/MCB.26.6.2093-2108.2006.PubMed CentralView ArticlePubMed
- Xie S, Xie B, Lee MY, Dai W: Regulation of cell cycle checkpoints by polo-like kinases. Oncogene. 2005, 24 (2): 277-286. 10.1038/sj.onc.1208218.View ArticlePubMed
- Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R, Rouyrre N, Trommeshauser D, Hoesl CE, Munzert G: Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2008, 26 (34): 5511-5517. 10.1200/JCO.2008.16.1547.View ArticlePubMed
- Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, Barriuso J, Medani H, Degenhardt Y, Allred AJ, et al: Phase I study of GSK461364, a specific and competitive Polo-like Kinase 1 (PLK1) inhibitor in patients with advanced solid malignancies. Clin Cancer Res. 2011, 17 (10): 3420-3430. 10.1158/1078-0432.CCR-10-2946.View ArticlePubMed
- Ackermann S, Goeser F, Schulte JH, Schramm A, Ehemann V, Hero B, Eggert A, Berthold F, Fischer M: Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma. Clin Cancer Res. 2011, 17 (4): 731-741. 10.1158/1078-0432.CCR-10-1129.View ArticlePubMed
- Hu K, Lee C, Qiu D, Fotovati A, Davies A, Abu-Ali S, Wai D, Lawlor ER, Triche TJ, Pallen CJ, et al: Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther. 2009, 8 (11): 3024-3035. 10.1158/1535-7163.MCT-09-0365.PubMed CentralView ArticlePubMed
- Barton VN, Donson AM, Kleinschmidt-DeMasters BK, Birks DK, Handler MH, Foreman NK: Unique molecular characteristics of pediatric myxopapillary ependymoma. Brain Pathol. 2010, 20 (3): 560-570. 10.1111/j.1750-3639.2009.00333.x.PubMed CentralView ArticlePubMed
- El-Sheikh A, Fan R, Birks D, Donson A, Foreman NK, Vibhakar R: Inhibition of Aurora Kinase A enhances chemosensitivity of medulloblastoma cell lines. Pediatr Blood Cancer. 2010, 55 (1): 35-41.PubMed
- Venkataraman S, Alimova I, Fan R, Harris P, Foreman N, Vibhakar R: MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence. PLoS One. 2010, 5 (6): e10748-10.1371/journal.pone.0010748.PubMed CentralView ArticlePubMed
- Liu X, Erikson RL: Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA. Proc Natl Acad Sci USA. 2002, 99 (13): 8672-8676. 10.1073/pnas.132269599.PubMed CentralView ArticlePubMed
- Li M, Lee KF, Lu Y, Clarke I, Shih D, Eberhart C, Collins VP, Van Meter T, Picard D, Zhou L, et al: Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell. 2009, 16 (6): 533-546. 10.1016/j.ccr.2009.10.025.PubMed CentralView ArticlePubMed
- Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, Boca SM, Carter H, Samayoa J, Bettegowda C, et al: The genetic landscape of the childhood cancer medulloblastoma. Science. 2011, 331 (6016): 435-439. 10.1126/science.1198056.PubMed CentralView ArticlePubMed
- Janssen A, Medema RH: Mitosis as an anti-cancer target. Oncogene. 2011, 30 (25): 2799-2809. 10.1038/onc.2011.30.View ArticlePubMed
- Chopra P, Sethi G, Dastidar SG, Ray A: Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert Opin Investig Drugs. 2010, 19 (1): 27-43. 10.1517/13543780903483191.View ArticlePubMed
- Jeong K, Jeong JY, Lee HO, Choi E, Lee H: Inhibition of Plk1 induces mitotic infidelity and embryonic growth defects in developing zebrafish embryos. Dev Biol. 2010, 345 (1): 34-48. 10.1016/j.ydbio.2010.06.004.View ArticlePubMed
- Lu LY, Wood JL, Minter-Dykhouse K, Ye L, Saunders TL, Yu X, Chen J: Polo-like kinase 1 is essential for early embryonic development and tumor suppression. Mol Cell Biol. 2008, 28 (22): 6870-6876. 10.1128/MCB.00392-08.PubMed CentralView ArticlePubMed
- Gerster K, Shi W, Ng B, Yue S, Ito E, Waldron J, Gilbert R, Liu FF: Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2010, 77 (1): 253-260. 10.1016/j.ijrobp.2009.11.027.View ArticlePubMed
- Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB: Identification of human brain tumour initiating cells. Nature. 2004, 432 (7015): 396-401. 10.1038/nature03128.View ArticlePubMed
- Singh SK, Clarke ID, Hide T, Dirks PB: Cancer stem cells in nervous system tumors. Oncogene. 2004, 23 (43): 7267-7273. 10.1038/sj.onc.1207946.View ArticlePubMed
- Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, Haslinger C, Garin-Chesa P, Adolf GR: BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res. 2009, 15 (9): 3094-3102. 10.1158/1078-0432.CCR-08-2445.View ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/80/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.